Search News


Browse Archives

News

Clarion Call for More NIH Funding

March 12, 2008

Share This Story

FREE Daily News Alerts

Advertisement

In recent years, many university presidents or scientific societies have called for more federal support for research.

On Tuesday, however, in announcing a new report on the "broken pipeline" for young researchers, a particularly high-powered coterie of presidents and professors argued forcefully for a significant increase in funding for the National Institutes of Health. Most prominent among them was Drew Gilpin Faust, the president of Harvard University and a historian who has been speaking out about biomedical research questions that are most serious at institutions that lack her university's resources.

"We are here today because five years of flat funding of the budget of NIH is putting America at risk," Faust said at the morning announcement at the National Press Club, adding that shortages are "discouraging our best and brightest researchers."

The report, a follow-up to one released a year ago, has a particularly alarmist take on NIH funding levels over the past several years.

"Science itself is taking a hit," the report says. "As the NIH has less grant money to award, the scientists who review grant applications are predictably becoming more and more risk averse in their evaluations, preferring to see incremental steps rather than bold visions. This conservatism among reviewers is changing the way researchers write grant applications and design experiments. There has been a fundamental narrowing of the scientific vision, with the primary scientific query shifting from 'what is possible?' to 'what is fundable?'"

The report offers several statistics that the assembled panel cited both at the announcement and at a hearing later that morning before the Senate Committee on Health, Education, Labor and Pensions:

  • The overall success rate for the vital NIH R01 (or Research Project) grants, or their equivalents, decreased from 32 percent in 1999 to 24 percent last year.
  • The success rate for applications on their first submission dropped from 29 percent in 1999 to 12 percent last year.
  • The average age of researchers receiving their first R01 grant was 43 last year, compared with 39 in 1990.
  • A quarter of R01 grants go to first-time investigators, compared with 29 percent in 1990.

NIH funding was doubled between 1997 and 2003, but since then its levels have marginally increased each year. According to the report, the agency's purchasing power in real dollars decreased by 13 percent since 2003.

"The effects of the NIH budget constraints are cascading down the academic research pipeline, causing leaks and clogs along the way," it said.

The report and its supporters emphasized that the funding situation would particularly disadvantage young scientists -- or those thinking about pursuing science -- just beginning their careers.

At the committee hearing, Sen. Edward M. Kennedy (D-Mass.) quoted the concerns of Joshua Boger, the CEO of Vertex Pharmaceuticals and president of the Biotechnology Industry Organization: “You can lose a generation of researchers pretty fast -- in 5 or 10 years. You create such a discouraging atmosphere they just go somewhere else instead of academic research. We don’t have to lose 50,000 researchers, just 50 really good ones. Once it happens, we won’t get those people back.”

The research establishment is setting its sights on the budget process and a typically bipartisan consensus on science funding. The number being floated around the halls of Congress, said Kevin Casey, Harvard's associate vice president of government, community and public affairs, is 6.7 -- as in a 6.7-percent increase in NIH funding for fiscal year 2009.

Advocates have circulated a "Dear Colleague" letter in the House of Representatives, and in the Senate, an amendment to the budget bill that would allocate an extra $2.1 billion for the agency has the support of Kennedy, Sen. Hillary Clinton (D-N.Y.) and Sen. Arlen Specter (R-Pa.), among others. Already, the Senate budget resolution recommends $30 billion for the NIH, or $950 million over the 2008 appropriation.

The budget amendment doesn't specify where the extra funding would come from. "I think that's for Congress to figure out, not for me to figure out," Faust said about allocating the necessary funds.

The Harvard president came under fire from some quarters in recent weeks for seeming to belittle the research contributions of public universities and suggesting that they focus on social science and less ambitious projects instead, a charge that she disputed. Business Week, which printed the original remarks, later admitted that the quotes had been out of context. She emphasized at the announcement that the institutions represented in the report -- including Duke University, Brown University, the Ohio State University Medical Center and others -- "share in this partnership with the federal government and we are in this all together."

See all postings »
Advertisement
Advertisement

Matching Jobs

Comments on Clarion Call for More NIH Funding

  • Posted by JBM on March 12, 2008 at 7:55am EDT
  • Perhaps the research is sufficiently important that Harvard can spare a few of its billions of dollars to support it?

  • There will never be enough
  • Posted by Robert on March 12, 2008 at 9:05am EDT
  • I am a faculty member in an academic health sciences center, where what I'm about to say is considered blasphemy. Nevertheless, the claim that the “flat funding… is putting America at risk” is self-serving poppycock. The shortage of funds for new investigators is self-inflicted by the major universities. When the government announced its plans to double NIH funding between 1997 and 2003, many universities immediately built new research buildings, expanded their research faculty and graduate programs, and thereby increased the number of newly minted Ph.D.s who would then join in the scramble for grant money. By more than doubling the number of faculty competing for NIH money, the universities guaranteed it would be more difficult for new investigators to get funding. I’m certain that if the NIH announced they were going to again double the grant budget over the next five years, Harvard, Duke, Ohio State etc. would again double the number of research faculty and graduate students, then in six years again complain it was too hard for these new Ph.D.s to get funded. The research universities have an unquenchable thirst for federal grant money and there will never be enough to satisfy them.

  • Posted by RandomScientist on March 12, 2008 at 9:55am EDT
  • As a faculty member at the medical school of an R1 university, I agree 100% with Robert. In discussing the funding crisis there has been too much focus on the behavior of the NIH and not nearly enough on the behavior of universities.

    The decision by many universities to massively expand their programs and facilities with no financial plan beyond "the NIH will pay" has been largely responsible for the current situation (I suspect placing limits on the amount of faculty salary that comes from soft money might help discourage this behavior).

    I also agree with Robert that, sadly, administrators appear to have learned nothing from this last boom and bust cycle, and will likely behave exactly the same way the next time the NIH budget increases.

  • Posted by Harvard at Scientist on March 13, 2008 at 5:30am EDT
  • Faust is right on. America will quickly lose its edge in science. Besides, our solutions to cancer and heart disease have been flat for years. This should be entirely nonpartisan and our funding should continue with or without a war. America needs leadership from the top. We once had the presidency calling for the success of the space program. Today there is no leadership.

  • Dying on the Vine
  • Posted by Denis , Asst Prof at A Big U. on August 15, 2008 at 10:30pm EDT
  • I am one of those you investigators. I started off with all of the promise of a new lab and a Career Award. Yet, I find myself 5 yrs later with bleak prospects for NIH funds and facing tenure. A system that kills its young and their creative ideas is destined to pay a greater longterm price.